BioNTech (NASDAQ:BNTX) CEO Sells 17,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 17,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00. Following the completion of the sale, the chief executive officer directly owned 197,209 shares of the company’s stock, valued at approximately $19,219,989.14. This represents a 7.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.

BioNTech Trading Up 0.1%

BioNTech stock traded up $0.05 during trading hours on Friday, reaching $96.90. The company had a trading volume of 681,351 shares, compared to its average volume of 1,087,641. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a 50-day moving average price of $98.66 and a 200 day moving average price of $94.99. The firm has a market cap of $24.50 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period last year, the company posted ($1.60) EPS. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. Equities analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Engineers Gate Manager LP increased its position in shares of BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after buying an additional 1,833 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in BioNTech in the second quarter worth about $39,000. Nykredit A S bought a new stake in BioNTech during the 2nd quarter valued at approximately $293,000. B. Metzler seel. Sohn & Co. AG boosted its position in BioNTech by 66.7% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after acquiring an additional 4,390 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of BioNTech during the 2nd quarter worth approximately $2,520,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on BNTX. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. UBS Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Finally, Berenberg Bank set a $140.00 price target on BioNTech in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.